United States

Evotec AG (EVTG.DE)

EVTG.DE on Xetra

11:35am EDT
Change (% chg)

€0.07 (+1.41%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for EVTG.DE


Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for... (more)


Beta: 0.76
Market Cap(Mil.): €670.85
Shares Outstanding(Mil.): 132.84
Dividend: --
Yield (%): --


  EVTG.DE Industry Sector
P/E (TTM): 106.90 44.78 33.70
EPS (TTM): 0.05 -- --
ROI: 2.52 2.97 13.98
ROE: 3.42 3.01 14.91

BRIEF-Evotec plans to acquire Cyprotex for 62 mln eur

* Offer is intended to be implemented by a scheme of arrangement regulated by uk takeover code, with already >50% shares secured irrevocable

Oct 26 2016

BRIEF-Evotec signs deal to cooperate with UCB on in vitro pharmacology

* Under terms of three-year agreement, evotec will support UCB's in vitro pharmacology team in drug discovery projects across multiple target classes, particularly in cns space

Oct 20 2016

BRIEF-Evotec, Carrick Therapeutics agree strategic alliance

* Evotec contributes $6 million to Carrick's $95 million funding round through a top-class global investor consortium

Oct 04 2016

BRIEF-Evotec: further pre-clinical milestone in endometriosis alliance with Bayer

* Says evotec receives further important pre-clinical milestone in endometriosis alliance with bayer

Sep 29 2016

BRIEF-Evotec says enters research collaboration with Inserm in oncology

* Says enters into an oncology research collaboration with Inserm, the private subsidiary of the French National Institute of Health and Medical Research Source text for Eikon: Further company coverage:

Sep 22 2016

BRIEF-Evotec, Bayer to develop new treatments to fight kidney diseases

* Says goal is development of multiple clinical candidates for treatment of kidney diseases such as chronic kidney disease in diabetes patients

Sep 21 2016

BRIEF-Evotec reports 37 pct rise in revenues in H1

* Profitability guidance raised and positive outlook confirmed

Aug 10 2016

BRIEF-Evotec achieves milestone in alliance with Bayer

* news: evotec achieves clinical development milestone as part of its multi-target alliance with bayer in endometriosis

Aug 04 2016

BRIEF-Evotec to begin drug discovery collaboration with Research UK

* Evotec awarded contract from antibiotic Research UK to begin integrated drug discovery collaboration

Jul 11 2016

BRIEF-Evotec enters licence agreement for access to gene editing technology

* enters licence agreement for access to crispr-cas9 gene editing technology

Jul 06 2016

Earnings vs. Estimates